| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
PSI-6130 (R-1656) is a novel, potent and selective inhibitor of HCV NS5B polymerase which inhibits HCV replication with a mean IC50 of 0.6 μM. PSI-6130 is a cytidine analogue with potent and selective anti-hepatitis C virus (HCV) activity in the subgenomic HCV replicon assay, 90% effective concentration (EC90)=4.6 +/- 2.0 microM. The spectrum of activity and cytotoxicity profile of PSI-6130 was evaluated against a diverse panel of viruses and cell types, and against two additional HCV-1b replicons.
| Targets |
HCV replication(IC50= 0.6 μM)
|
|---|---|
| ln Vitro |
Strong and targeted inhibitory activity of PSI-6130 is shown against HCV RNA replication mediated by the NS5B polymerase. With mean EC50 values of 0.51 and 0.30 μM, respectively, PSI-6130 inhibits the subgenomic RNA replication of HCV GT-1b (Con1 strain) and GT-1a (H77 strain). At an EC50 of 0.51 μM, PSI-6130 inhibits 40% of human serum[1]. With a mean IC50 of 0.6 μM, PSI-6130 inhibits HCV replication, while PSI-6130-TP inhibits HCV replicase with a mean IC50 of 0.34 μM. With an IC50 of 0.13 μM and a Ki of 0.023 μM, PSI-6130-TP inhibits recombinant HCV Con1 NS5B on a heteropolymeric RNA template derived from the 3′-end of the HCV genome[2].
|
| Enzyme Assay |
Using a complement strand of internal ribosomal entry site (cIRES) RNA template, the incorporation of radiolabeled NMP into acid-insoluble RNA products is used to measure the potency of compounds in inhibiting the RdRp activity of recombinant NS5B570-BK, NS5B570-Con1, and NS5B570-H77 proteins. In summary, 200 nM in vitro-transcribed cIRES RNA template, 1 μCi of tritiated UTP (42 Ci/mmol), 500 μM ATP, 500 μM GTP, 1 μM CTP, 1× TMDN buffer (40 mM Tris-HCl [pH 8.0], 4 mM MgCl2, 4 mM dithiothreitol, 40 mM NaCl), and 200 nM enzyme are used to determine 50% inhibitory concentration (IC50). Under the conditions of the GT-1b assay, compounds are tested for their ability to inhibit the RdRp activity of NS5B570-S282T-Con1; NS5B570-BK and NS5B570-Con1 enzymes are used as controls. 50 μL is the final reaction volume for all assay settings. There is a final 10% dimethyl sulfoxide in every reaction. Values Km and Ki are measured.
|
| References |
|
| Molecular Formula |
C10H14N3O4F
|
|---|---|
| Molecular Weight |
259.23426
|
| Exact Mass |
259.096
|
| Elemental Analysis |
C, 46.33; H, 5.44; F, 7.33; N, 16.21; O, 24.69
|
| CAS # |
817204-33-4
|
| PubChem CID |
6481236
|
| Appearance |
White to off-white solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
482.4±55.0 °C at 760 mmHg
|
| Flash Point |
245.5±31.5 °C
|
| Vapour Pressure |
0.0±2.7 mmHg at 25°C
|
| Index of Refraction |
1.653
|
| LogP |
-0.72
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
18
|
| Complexity |
427
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C[C@]1([C@H](O)[C@@H](CO)O[C@H]1N1C=CC(N)=NC1=O)F
|
| InChi Key |
NYPIRLYMDJMKGW-UZRKRJFESA-N
|
| InChi Code |
InChI=1S/C10H14FN3O4/c1-10(11)7(16)5(4-15)18-8(10)14-3-2-6(12)13-9(14)17/h2-3,5,7-8,15-16H,4H2,1H3,(H2,12,13,17)/t5-,7-,8-,10+/m1/s1
|
| Chemical Name |
4-amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidin-2(1H)-one
|
| Synonyms |
PSI-6130; PSI-6130; PSI-6130; R 1656; R-1656; R1656.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~96.44 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.64 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.64 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.5 mg/mL (9.64 mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8576 mL | 19.2879 mL | 38.5758 mL | |
| 5 mM | 0.7715 mL | 3.8576 mL | 7.7152 mL | |
| 10 mM | 0.3858 mL | 1.9288 mL | 3.8576 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA